Meltem Asicioglu

Meltem Asicioglu

Auto-generated profile, based on publicly available information

Meltem Asicioglu

TÜBİTAK National Metrology Institute, Kocaeli, Turkiye

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2024 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
MAMeltem Asicioglu
Meltem Asicioglu
CSClaudia Swart
Claudia Swart
ESEvren Saban
Evren Saban
EYEmrah Yurek
Emrah Yurek
NKNevin Gul Karaguler
Nevin Gul Karaguler
MOMerve Oztug
Merve Oztug
Objectives: An analytical protocol based on isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS), which includes a peptide-based calibration strategy, was developed and validated for the determination of cardiac troponin I (cTnI) levels in clinical samples. Additionally, the developed method was compared with a protein-based calibration strategy, using cTnI serving as a model for low-abundant proteins. The aim is to evaluate new approaches for protein quantification in complex matrices, supporting the metrology community in implementing new methods and developing fit-for-purpose SI- traceable peptide or protein primary calibrators. Methods: To establish traceability to SI units, peptide impurity correction amino acid analysis (PICAA) was conducted to determine the absolute content of signature peptides in the primary standards. Immunoaffinity enrichment was used to capture cTnI from human serum, with a comparison between microbeads and nanobeads to improve enrichment efficiency. Parallel reaction monitoring was used to monitor two signature peptides specific to cTnI. Various digestion parameters were optimized to achieve complete digestion. Results: The analytical method demonstrated selectivity and specificity, allowing the quantification of cTnI within 0.9–22.0 μg/L. The intermediate precision RSD was below 28.9 %, and the repeatability RSD was below 5.8 % at all concentration levels, with recovery rates ranging from 87 % to 121 %. The comparison of calibration strategies showed similar LOQ values, but the peptide-based calibration exhibited significant quantitative bias in recovery rates. The data are available via ProteomeXchange (PXD055104). Conclusions: This isotope dilution liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) method, based on peptide calibration, successfully quantified cTnI in human serum. Comparing this with protein-based calibration highlighted both the strengths and potential limitations of peptide-based strategies.

12 January 2024 in Accreditation and Quality Assurance
Verified
Journal Article
Closed access
PDF file
MOMerve Oztug
Merve Oztug
ESEvren Saban
Evren Saban
MAMeltem Asicioglu
Meltem Asicioglu
AIAlper Isleyen
Alper Isleyen
MAMuslum Akgoz
Muslum Akgoz

14 April 2026 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
MOMerve Oztug
Merve Oztug
MAMeltem Aşicioğlu
Meltem Aşicioğlu
KAKonca Altinkaynak
Konca Altinkaynak
EKEvren Kilinç
Evren Kilinç
Background/aim: Acute myocardial infarction (AMI) triggers systemic biochemical responses, including dynamic changes in the phosphorylation status of circulating proteins. However, the phosphoproteomic profile of serum in the context of AMI remains insufficiently characterized. This study aimed to investigate serum phosphoproteomic alterations associated with AMI and to explore potential correlations with markers of cardiac injury. Materials and methods: A comparative phosphoproteomic analysis was performed on serum samples obtained from eight patients with AMI and pooled healthy control samples. High-abundance serum proteins were depleted, and phosphopeptides were enriched using TiO2 phosphopeptide enrichment kit. Samples were analyzed by liquid chromatography–tandem mass spectrometry using a Q Exactive HF-X Orbitrap mass spectrometer. Data were searched against the Homo sapiens database using Sequest HT with a 1% false discovery rate and were quantified by label-free quantification using Proteome Discoverer version 2.4. Results: A total of 46 phosphoproteins were confidently identified, revealing distinct phosphorylation profiles between AMI and control samples. Increased phosphorylation levels were observed for solute carrier family 12 member 5, apolipoprotein L1, the low-molecular-weight isoform of kininogen-1, and osteopontin in AMI serum. Conversely, phosphorylated inter-alpha-trypsin inhibitor heavy chain H2, antithrombin III, histidine-rich glycoprotein, peroxiredoxin-4, GTPase ERas, and the 26S proteasome non-ATPase regulatory subunit 1 were reduced or undetectable. A strong negative correlation was found between apolipoprotein L1 phosphorylation and cardiac troponin I concentrations (r = –0.91; p = 0.0016). Conclusion: These findings demonstrate that serum phosphoproteomics can provide valuable insights into the molecular events associated with AMI. The inverse relationship between apolipoprotein L1 phosphorylation and cardiac troponin I levels suggests that phosphoproteomic profiling may aid in understanding myocardial injury mechanisms.